Predicting COVID-19 progression from diagnosis to recovery or death linking primary care and hospital records in Castilla y León (Spain).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 20 05 2021
accepted: 03 09 2021
entrez: 20 9 2021
pubmed: 21 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

This paper analyses COVID-19 patients' dynamics during the first wave in the region of Castilla y León (Spain) with around 2.4 million inhabitants using multi-state competing risk survival models. From the date registered as the start of the clinical process, it is assumed that a patient can progress through three intermediate states until reaching an absorbing state of recovery or death. Demographic characteristics, epidemiological factors such as the time of infection and previous vaccinations, clinical history, complications during the course of the disease and drug therapy for hospitalised patients are considered as candidate predictors. Regarding risk factors associated with mortality and severity, consistent results with many other studies have been found, such as older age, being male, and chronic diseases. Specifically, the hospitalisation (death) rate for those over 69 is 27.2% (19.8%) versus 5.3% (0.7%) for those under 70, and for males is 14.5%(7%) versus 8.3%(4.6%)for females. Among patients with chronic diseases the highest rates of hospitalisation are 26.1% for diabetes and 26.3% for kidney disease, while the highest death rate is 21.9% for cerebrovascular disease. Moreover, specific predictors for different transitions are given, and estimates of the probability of recovery and death for each patient are provided by the model. Some interesting results obtained are that for patients infected at the end of the period the hazard of transition from hospitalisation to ICU is significatively lower (p < 0.001) and the hazard of transition from hospitalisation to recovery is higher (p < 0.001). For patients previously vaccinated against pneumococcus the hazard of transition to recovery is higher (p < 0.001). Finally, internal validation and calibration of the model are also performed.

Identifiants

pubmed: 34543345
doi: 10.1371/journal.pone.0257613
pii: PONE-D-21-15447
pmc: PMC8451995
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0257613

Subventions

Organisme : Medical Research Council
ID : MC_UU_00002/16
Pays : United Kingdom

Déclaration de conflit d'intérêts

No authors have competing interests.

Références

Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Lancet Respir Med. 2021 Apr;9(4):397-406
pubmed: 33600777
Clin Epidemiol. 2020 Sep 03;12:925-928
pubmed: 32943941
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
PLoS One. 2020 Nov 12;15(11):e0242127
pubmed: 33180830
J Am Med Inform Assoc. 2021 Jun 12;28(6):1188-1196
pubmed: 33479727
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Medicine (Baltimore). 2021 Aug 13;100(32):e26900
pubmed: 34397917
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Am J Epidemiol. 2021 Apr 6;190(4):539-552
pubmed: 33351077
Stat Med. 2007 May 20;26(11):2389-430
pubmed: 17031868
Lancet Respir Med. 2021 Jul;9(7):773-785
pubmed: 34000238
Sci Rep. 2021 Jan 13;11(1):1137
pubmed: 33441892
Front Public Health. 2020 Dec 08;8:585850
pubmed: 33425835

Auteurs

Pedro C Álvarez-Esteban (PC)

Department of Statistics and Operations Research, Universidad de Valladolid, Valladolid, Spain.

Eustasio Del Barrio (E)

Department of Statistics and Operations Research, Universidad de Valladolid, Valladolid, Spain.

Oscar M Rueda (OM)

MRC-Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.

Cristina Rueda (C)

Department of Statistics and Operations Research, Universidad de Valladolid, Valladolid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH